D8534C00001

RECRUITMENT COMPLETED 

Research code: D8534C00001
Research name: Randomised, double-blind, Phase III research evaluating a change of treatment to the AZD9833 regimen (next-generation oral SERD) in combination with a CDK4/6 inhibitor (palbocyclizib or abemacyclizib) compared with continued treatment with an aromatase inhibitor (letrozole or anastrozole) in combination with a CDK4/6 inhibitor in patients with advanced hormone receptor-positive (HR+) breast cancer without HER2 overexpression (HER2- ) with detectable estrogen receptor gene mutation (ESR1), with no disease progression during first-line treatment with an aromatase inhibitor regimen in combination with a CDK4/6 inhibitor - a research with early treatment change dependent on ctDNA diagnosis (Serena)
Indication: breast cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients treated for breast cancer with palbocyclib or abemacyclib in combination with an aromatase inhibitor, after one year of therapy with improvement
Research drug: new generation hormone therapy (SERD) in combination with CDK4/6 inhibitors